Dose dependent pharmacokinetics of albendazole in human
β Scribed by A. Mirfazaelian; M. R. Rouini; S. Dadashzadeh
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 78 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0142-2782
- DOI
- 10.1002/bdd.327
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The pharmacokinetics of one of the most widely used non-steroidal antiinflammatory drugs, naproxen, were studied in 28 healthy human volunteers at the two most commonly used dose levels, viz., 250 mg and 500 mg, in a cross-over design. The plasma levels of naproxen were analysed by a modified high-p
The aim of this study was to assess the pharmacokinetic profile of pancopride after repeated oral dose administration of 20mg pancopride in tablet form once a day for 5 d in 12 healthy male volunteers. Plasma levels were measured by HPLC using a solid phase extraction method and automated injection.
## Abstract The pharmacokinetics after oral administration of 200, 600 or 1200 mg of __N__βacetylcysteine (NAC) were studied in 10 healthy subjects. Normalized maximal plasma concentration was significantly higher after a 600 mg dose than after a 200 mg dose. Bioavailability of NAC significantly in
Therapeutic drug monitoring of albendazole: Determination of albendazole, albendazole sulfoxide, and albendazole sulfone in human plasma using nonaqueous capillary electrophoresis A nonaqueous capillary electrophoretic method (NACE) for the fast determination of plasma levels of albendazole (ABZ), a